Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 8/20 | 0.49 |
| ▸ | HCK | P08631 | 9/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311923 | 0.89 | NR3C2 (0.44) | NR3C2HCKMAPK14MAPK12SRC | |
| SCHEMBL2309475 | 0.85 | POLB (0.45) | NR3C2HCKMAPK14MAPK12SRC | |
| SCHEMBL2309465 | 0.85 | POLB (0.45) | NR3C2HCKMAPK14MAPK12SRC | |
| SCHEMBL12320352 | 0.85 | NR3C2 (0.38) | NR3C2HCKMAPK14MAPK12SRC | |
| SCHEMBL1979137 | 0.83 | NR3C2 (0.51) | NR3C2HCKMAPK14MAPK12 | |
| SCHEMBL1979511 | 0.81 | AAK1 (0.46) | NR3C2HCKMAPK14MAPK12SRC | |
| SCHEMBL1981716 | 0.81 | NR3C2 (0.50) | NR3C2HCKMAPK14MAPK12AAK1 | |
| SCHEMBL13331029 | 0.77 | GCK (0.49) | HCKMAPK14MAPK12SRC | |
| SCHEMBL2405918 | 0.76 | MAPK14 (0.75) | HCKMAPK14MAPK12SRC | |
| SCHEMBL2405921 | 0.76 | MAPK14 (0.51) | NR3C2HCKMAPK14MAPK12AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975285-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2015-03-10 | — | — | US | disclosed |
| US-20140114064-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2014-04-24 | — | — | US | disclosed |
| US-8618140-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD (GB) | 2013-12-31 | — | — | US | disclosed |
| US-20130012512-A1 | P38 MAP kinase inhibitors | ITO KAZUHIRO (GB) | 2013-01-10 | — | — | US | disclosed |
| US-8293748-B2 | p38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-23 | — | — | US | disclosed |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-09-01 | — | — | US | disclosed |
| EP-2350049-A2 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010038086-A2 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012512-A1 | P38 MAP kinase inhibitors | MAPK1, MAPK3, MAPK6 | NR3C2 84/4885HCK 2830/4885MAPK14 33/4885 |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAPK3, MAPK6 | NR3C2 84/4885HCK 2830/4885MAPK14 33/4885 |
| US-20140114064-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAPK3, MAPK6 | NR3C2 84/4885HCK 2830/4885MAPK14 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.